Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs
Autore:
Roon, KI; Sandor, PS; Schoonman, GG; Lamers, FPL; Schoenen, J; Ferrari, MD; van Dijk, JG;
Indirizzi:
Leiden Univ, Med Ctr, Dept Neurol & Clin Neurophysiol, NL-2300 RC Leiden, Netherlands Leiden Univ Leiden Netherlands NL-2300 RC NL-2300 RC Leiden, Netherlands Univ Liege, Hosp CHR Citadelle, Dept Neurol, B-4000 Liege, Belgium Univ Liege Liege Belgium B-4000 elle, Dept Neurol, B-4000 Liege, Belgium
Titolo Testata:
CEPHALALGIA
fascicolo: 10, volume: 19, anno: 1999,
pagine: 880 - 885
SICI:
0333-1024(199912)19:10<880:AEPITA>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
AGONIST ZOLMITRIPTAN 311C90; INTENSITY DEPENDENCE; SEROTONERGIC NEUROTRANSMISSION; 5HT(1B/1D) AGONIST; TRIGEMINAL NEURONS; RECEPTOR AGONIST; MIGRAINE; SUMATRIPTAN; STIMULATION; SITES;
Keywords:
central effects; intensity dependence of auditory evoked potentials; migraine; power calculations; triptans;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: van Dijk, JG Leiden Univ, Med Ctr, Dept Neurol & Clin Neurophysiol, POB 9600, NL-2300 RC Leiden, Netherlands Leiden Univ POB 9600 Leiden NetherlandsNL-2300 RC therlands
Citazione:
K.I. Roon et al., "Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs", CEPHALALGIA, 19(10), 1999, pp. 880-885

Abstract

Because the "intensity dependence" of cortical auditory evoked potentials (IDAP) is under serotonergic control, it can be used to assess central antimigraine effects of 5HT(1B/1D) agonists. We measured IDAP before and 2 h after naratriptan (5 mg, n = 19) and zolmitriptan (5 mg, n=19) in healthy volunteers, IDAP was expressed as the amplitude-stimulus intensity function ("ASF slope"). Naratriptan tended to increase ASF dope (mean difference 0.23+/-0.62 mu V/10 dB, p=0.06) while zolmitriptan (0.08+/-0.95 mu V/10 db, p=0.35) did not. We assessed the suitability of IDAP for measuring central antimigraine drug effects using repeatability data (see companion paper). We calculated the trade-off between the size of the expected drug effects (ASF slope difference) and the necessary sample size. Because of poor repeatability 36 to 80 subjects are required to detect ASF slope changes in the 0.25-0.5 mu V/10 db range. These data can be used to design trials using IDAP.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 17:06:15